UCB SA (OTCMKTS:UCBJF) Short Interest Down 17.0% in October

UCB SA (OTCMKTS:UCBJF - Get Free Report) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 403,500 shares, a decline of 17.0% from the October 15th total of 486,100 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 4,035.0 days.

UCB Stock Performance

UCBJF remained flat at $194.76 on Friday. 1,061 shares of the company were exchanged, compared to its average volume of 317. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $181.79 and a two-hundred day moving average of $157.75. UCB has a 12-month low of $72.25 and a 12-month high of $194.76.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.